<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269021</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-1005</org_study_id>
    <nct_id>NCT01269021</nct_id>
  </id_info>
  <brief_title>An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)</brief_title>
  <official_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhi-Hong Liu, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open,
      prospective, randomized parallel study to access the efficacy and safety of MMF compared to
      corticosteroid .

      Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the
      MMF group or corticosteroid group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To access the efficacy and safety of MMF compared to corticosteroid in in treatment of
      proliferative IgA Nephropathy(IgAN).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of complete remission (CR) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of overall response (CR+ partial remission [PR]) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the median time to CR</measure>
    <time_frame>from the start of enrollment to the day of complete remission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the relapse rate after stopping the treatments</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>IgA Nephropathy (IgAN)</condition>
  <arm_group>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil plus lower dose of Prednisone</intervention_name>
    <description>MMF 1.0-1.5g/d*6mons Prednisone 0.4-0.6 mg/kg/d</description>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone in full dose</intervention_name>
    <description>0.8-1mg/kg/d</description>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who signed written informed consent form

          2. age between 18-60 years, female or male

          3. diagnosed IgA Nephropathy (IgAN) by renal biopsy during 1 months

          4. renal biopsy had: 10%&lt; crescents&lt;50%; endocapillary hypercellularity; or necrosis ,and
             interstitial fibrosis&lt;50%,

          5. proteinuria&gt;1g/24h for two times

        Exclusion Criteria:

          1. secondary IgA Nephropathy (IgAN);

          2. eGFR&lt;30ml/min/1.73m2.( MDRD formula)

          3. liver disfunction;

          4. uncontrolled hypertension

          5. WBC &lt;3000/mm3

          6. Severe viral infection(HBV, HCV, CMV) within 3 months ofor known HIV infection.

          7. diabetes or obesity(BMI&gt;28) ;

          8. severe infection or central nervous system symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihong Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhi-Hong Liu, M.D.</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>MMF treatment IgA Nephropathy (IgAN)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

